Pharmacologic management of obesity.
Recent discoveries of processes that govern regulation of body weight and energy expenditure have led to development of new anti-obesity pharmacological agents. This article will inform health professionals of new anti-obesity medications that target neuronal systems within the central nervous system (CNS) and peripheral humoral proteins that send signals to the CNS. An emerging theme of new therapies is to use combination medications that are directed toward several targets or leverage existing gastrointestinal satiety hormonal signals. By using combination therapies, it is anticipated that greater weight loss will be achieved compared to monotherapy.
Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA. rkushner@northwestern.edu
Robert F
RF
Kushner
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D001067:Appetite Depressants